TC Biopharm (Holdings) Plc (NASDAQ:TCBP) Short Interest Down 50.1% in November

TC Biopharm (Holdings) Plc (NASDAQ:TCBP) was the recipient of a significant decline in short interest during the month of November. As of November 30th, there was short interest totalling 19,100 shares, a decline of 50.1% from the November 15th total of 38,300 shares. Based on an average daily volume of 1,140,000 shares, the days-to-cover ratio is currently 0.0 days.

TC Biopharm Price Performance

TCBP traded down $0.05 during trading on Friday, hitting $0.53. The company’s stock had a trading volume of 337,796 shares, compared to its average volume of 499,384. TC Biopharm has a twelve month low of $0.44 and a twelve month high of $41.50. The firm’s 50 day moving average price is $1.85 and its 200-day moving average price is $5.35. The company has a current ratio of 1.12, a quick ratio of 0.88 and a debt-to-equity ratio of 0.67.

Analyst Upgrades and Downgrades

Separately, HC Wainwright lowered their price target on shares of TC Biopharm from $7.00 to $3.00 and set a “buy” rating on the stock in a research report on Friday, December 6th.

TC Biopharm Company Profile

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers.